Erschienen in:
01.12.2011
Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy
verfasst von:
Duk Joo Lee, Jeeyun Lee, Ha Yeon Lee, Taekyu Lim, Su Jin Lee, Seong Yoon Yi, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Young Suk Park
Erschienen in:
Medical Oncology
|
Sonderheft 1/2011
Einloggen, um Zugang zu erhalten
Abstract
The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in metastatic colorectal cancer (CRC) patients who have failed the standard oxaliplatin-based or irinotecan-based chemotherapy. From 2007 to 2010, metastatic CRC patients who received S-1 monotherapy as salvage treatment were identified from tumor registry at Samsung Medical Center. All patients received ≥ second-line treatment for CRC. S-1 was administered orally from day 1 to day 14, every 3 weeks. The dose of S-1 for each patient was determined according to body surface area (BSA) as follows: for BSA < 1.25 m2, 80 mg/day; for 1.25 m2 < BSA < 1.5 m2, 100 mg/day; and for BSA > 1.5 m2, 120 mg/day divided by 2 doses. The median age of the 19 patients was 59 years (range: 33–77). Fourteen (73.7%) of 19 patients received S-1 monotherapy as third-line treatment after failing oxaliplatin-based or irinotecan-based chemotherapy. Previous regimens prior to S-1 therapy were as follows: FOLFOX, XELOX, FOLFIRI, XELOX + avastin, and cetuximab + irinotecan. The median number of administered S-1 courses given in the entire studied population was 3 cycles (1–10 cycles). Three patients had confirmed partial response (PR) after 3 cycles of S-1 treatment. After a follow-up duration of 22.3 months (range: 6.7–32.6 months), median time to progression (TTP) was 2.1 (95% CI, 1.8–4.2) months. Median overall survival was 11.3 months (95% CI, 8.8–16.8) from the time of S-1 chemotherapy administration. Two patients had grade 1 hand-foot syndrome (HFS) after first and 2nd cycles of treatments, respectively, but treatments were continued without developing further adverse events. The salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy was moderately effective and well tolerated.